Osteoporosis Epidemiology Analysis and Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Osteoporosis Report Overview

In the 7MM, there were 20,291,551 diagnosed prevalent cases of osteoporosis in 2023. The diagnosed prevalent cases of osteoporosis will register an AGR of more than 1% during 2023-2033. Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a normal process known as remodeling, some of a person’s bone cells dissolve (resorption) and new bone cells grow back (formation). For people with osteoporosis, bone loss outpaces the growth of new bone. Consequently, bones become more porous and fragile, leading to weakness of the skeleton and an increased risk of hip, spine, and wrist fractures.

Osteoporosis Market Outlook, 2023-2033 (Diagnosed Prevalent Cases)

Osteoporosis Market Outlook, 2023-2033 (Diagnosed Prevalent Cases)

Buy the Full Report for More Insights into the Osteoporosis Market Forecast

Download a Free Report Sample

The Osteoporosis market research report provides an overview of the risk factors, comorbidities, and global and historical trends for osteoporosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report also includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of osteoporosis, and total and diagnosed prevalent cases of primary osteoporosis, segmented by sex and age (ages 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) in these markets.

Market Size (2023) 20,291,551 Cases
AGR (2023-2033) >1%
Forecast Period 2023-2033
Key Countries ·       The US

·       France

·       Germany

·       Spain

·       Italy

·       The UK

·       Japan

Key Sex Segments ·       Men

·       Women

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Osteoporosis Market Segmentation by Country

The key countries across the 7MM are the US, France, Germany, Spain, Italy, the UK, and Japan. In 2023, the US accounted for the highest percentage of diagnosed prevalent cases of osteoporosis in the 7MM. Since GlobalData epidemiologists held the diagnosed prevalence of osteoporosis constant for all the markets, any change in the diagnosed prevalent cases of osteoporosis in the 7MM is attributable to changing population demographics in the respective markets.

`Osteoporosis Market Analysis by Country, 2023 (%)

`Osteoporosis Market Analysis by Country, 2023 (%)

Buy the Full Report for More Country Insights into the Osteoporosis Market
Download a Free Report Sample

Osteoporosis Market Segmentation by Sex

Based on sex, the market can be segmented into men and women. In 2023, the diagnosed prevalent cases of osteoporosis in the 7MM were higher in women than men. Among the 7MM, Japan had the largest difference in the diagnosed prevalent cases of osteoporosis between men and women.

Osteoporosis Market Analysis by Sex, 2023 (%)

Osteoporosis Market Analysis by Sex, 2023 (%)

Buy the Full Report for More Sex Insights into the Osteoporosis Market

Download a Free Report Sample

Segments Covered in the Report

Osteoporosis Market Country Outlook (Diagnosed Prevalent Cases)

  • The US
  • France
  • Germany
  • Spain
  • Italy
  • The UK
  • Japan

Osteoporosis Market Sex Outlook (Diagnosed Prevalent Cases)

  • Men
  • Women

Scope

This report provides an overview of the risk factors, comorbidities, and global and historical trends for osteoporosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of osteoporosis, and total and diagnosed prevalent cases of primary osteoporosis, segmented by sex and age (ages 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) in these markets. In addition, this report provides a 10-year epidemiological forecast for the total and diagnosed prevalent cases of secondary osteoporosis, and total and diagnosed prevalent cases of osteopenia, segmented by sex. The report also includes the total and diagnosed prevalent cases of type 1 (postmenopausal) osteoporosis, the total and diagnosed prevalent cases of type 2 (age-associated/senile) osteoporosis, and total and diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use.

To forecast the total prevalent cases and diagnosed prevalent cases of osteoporosis and osteopenia in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the total prevalent cases of osteoporosis secondary to glucocorticoid use from primary market research. In addition, the forecast is supported by robust, country-specific data that were obtained from various authentic sources, such as research articles published in peer-reviewed journals.

Reasons to Buy

The Osteoporosis epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global MM market.

Quantify patient populations in the global Osteoporosis market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups that present the best opportunities for Osteoporosis therapeutics in each of the markets covered.

Table of Contents

  • 1. About GlobalData
  • 2. List of Contents

    • 2.1. List of Tables
    • 2.2. List of Figures

  • 3. Osteoporosis: Executive Summary

    • 3.1. Catalyst
    • 3.2. Related reports
    • 3.3. Upcoming reports

  • 4. Epidemiology

    • 4.1. Disease background
    • 4.2. Risk factors and comorbidities
    • 4.3. Global and historical trends
    • 4.4. 7MM forecast methodology

      • 4.4.1. Sources
      • 4.4.2. Forecast assumptions and methods
      • 4.4.3. Forecast assumptions and methods: total prevalent cases of osteoporosis
      • 4.4.4. Forecast assumptions and methods: diagnosed prevalent cases of osteoporosis
      • 4.4.5. Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of primary osteoporosis and secondary osteoporosis
      • 4.4.6. Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of type 1 and type 2 osteoporosis
      • 4.4.7. Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use
      • 4.4.8. Forecast assumptions and methods: total prevalent cases of osteopenia
      • 4.4.9. Forecast assumptions and methods: diagnosed prevalent cases of osteopenia

    • 4.5. Epidemiological forecast for osteoporosis (2023–33)

      • 4.5.1. Total prevalent cases of osteoporosis
      • 4.5.2. Age-specific total prevalent cases of osteoporosis
      • 4.5.3. Sex-specific total prevalent cases of osteoporosis
      • 4.5.4. Total prevalent cases of osteoporosis by primary and secondary osteoporosis
      • 4.5.5. Total prevalent cases of primary osteoporosis by type
      • 4.5.6. Total prevalent cases of osteoporosis secondary to glucocorticoid use
      • 4.5.7. Diagnosed prevalent cases of osteoporosis
      • 4.5.8. Age-specific diagnosed prevalent cases of osteoporosis
      • 4.5.9. Sex-specific diagnosed prevalent cases of osteoporosis
      • 4.5.10. Diagnosed prevalent cases of osteoporosis by primary and secondary osteoporosis
      • 4.5.11. Diagnosed prevalent cases of primary osteoporosis by type
      • 4.5.12. Diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use

    • 4.6. Discussion

      • 4.6.1. Epidemiological forecast insight
      • 4.6.2. COVID-19 impact
      • 4.6.3. Limitations of the analysis
      • 4.6.4. Strengths of the analysis

  • 5. Appendix

    • 5.1. Bibliography
    • 5.2. About the Authors

      • 5.2.1. Epidemiologist
      • 5.2.2. Reviewers
      • 5.2.3. Vice President of Disease Intelligence and Epidemiology

  • 6. Contact Us

Table

Table 1: Summary of updated data types

Table 2: Risk factors and comorbidities for osteoporosis

Figures

Figure 1: 7MM, total prevalent cases of osteoporosis, both sexes, N, ages ≥30 years, 2023 and 2033

Figure 2: 7MM, diagnosed prevalent cases of osteoporosis, both sexes, N, ages ≥30 years, 2023 and 2033

Figure 3: 7MM, total prevalence of osteoporosis, both sexes, ages ≥30 years, %, 2023

Figure 4: 7MM, diagnosed prevalence of osteoporosis, both sexes, ages ≥30 years, %, 2023

Figure 5: 7MM, sources used and not used to forecast total prevalent cases of osteoporosis

Figure 6: 7MM, sources used to forecast the total prevalent cases and diagnosed prevalent cases of primary and secondary osteoporosis

Figure 7: 7MM, sources used to forecast the total prevalent cases of osteopenia

Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of osteoporosis

Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of osteopenia

Figure 10: 7MM, total prevalent cases of osteoporosis, N, both sexes, ages ≥30 years, 2023

Figure 11: 7MM, age-specific total prevalent cases of osteoporosis, N, both sexes, 2023

Figure 12: 7MM, sex-specific total prevalent cases of osteoporosis, N, ages ≥30 years, 2023

Figure 13: 7MM, total prevalent cases of osteoporosis by primary osteoporosis and secondary osteoporosis, both sexes, ages ≥30 years, N, 2023

Figure 14: 7MM, total prevalent cases of primary osteoporosis by type, both sexes, ages ≥30 years, N, 2023

Figure 15: 7MM, total prevalent cases of osteoporosis secondary to glucocorticoid use, both sexes, ages ≥30 years, N, 2023

Figure 16: 7MM, diagnosed prevalent cases of osteoporosis, N, both sexes, ages ≥30 years, 2023

Figure 17: 7MM, age-specific diagnosed prevalent cases of osteoporosis, N, both sexes, 2023

Figure 18: 7MM, sex-specific diagnosed prevalent cases of osteoporosis, N, ages ≥30 years, 2023

Figure 19: 7MM, diagnosed prevalent cases of osteoporosis by primary osteoporosis and secondary osteoporosis, both sexes, ages ≥30 years, N, 2023

Figure 20: 7MM, diagnosed prevalent cases of primary osteoporosis by type, both sexes, ages ≥30 years, N, 2023

Figure 21: 7MM, diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use, both sexes, ages ≥30 years, N, 2023

Frequently asked questions

Osteoporosis Epidemiology Analysis and Forecast to 2033 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Osteoporosis Epidemiology Analysis and Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Osteoporosis Epidemiology Analysis and Forecast to 2033 in real time.

  • Access a live Osteoporosis Epidemiology Analysis and Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.